EcoDrugPlus

60s Ribosomal Protein L26

Ensembl ID : ENSPKIG00000002725
Gene Symbol: LOC111860719
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L8

Ensembl ID : ENSPKIG00000004287
Gene Symbol: LOC111856279
4 Cross references
204 Possible Orthologues:

72 Kda Type Iv Collagenase-Like

Ensembl ID : ENSPKIG00000002019
Gene Symbol: LOC111858175
3 Cross references
207 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPKIG00000004179
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPKIG00000004214
Gene Symbol: ABL1
3 Cross references
200 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPKIG00000007177
Gene Symbol: ABL1
4 Cross references
200 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSPKIG00000010769
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSPKIG00000003558
Gene Symbol: AKT1
1 Cross references
153 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSPKIG00000013946
Gene Symbol: AKT1
3 Cross references
186 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSPKIG00000001179
Gene Symbol: AKT2
4 Cross references
163 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSPKIG00000011969
Gene Symbol: AKT2
2 Cross references
210 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSPKIG00000022905
Gene Symbol: ALK
1 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).